Диссертация (1335925), страница 26
Текст из файла (страница 26)
Sofosbuvir with peginterfer-on-ribavirin for 12 weeks in previously treated patientswith hepatitis С genotype 2 or 3 and cirrhosis / E. Lawitz, F. Poordad, D. M. Brainard [et al.] //Hepatology. – 2015. – № 61 (3). P. 769–775.221. Lawitz, Е. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for noncirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis С infection. – P. a randomised,double-blind, phase 2 tria l / Е.
Lawitz, J. P. Lalezari, Т. Hassanein [et al.] // Lancet. Infect. Dis. –2013. – Vol. 13, N 5. – P. 401–408.222. Lee, S. Decreased IP-10 and elevated TGFβ1 levels are associated with viral clearancefollowing therapy in patients with hepatitis C virus / S. Lee, J. Varano, J. P. Flexman [et al.] // DiseaseMarkers. – 2010.223. Lee, W.
M. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy forchronic hepatitis С in previous interferon nonresponders / W. M. Lee, J. L. Dienstag, K. L. Lindsay [etal.] // Control Clin. Trials. – 2004. – № 25. – P. 472–492.224. Lenz, O. Virology analyses of HCV isolates from genotype 1-infected patients treated withsimeprevir plus peginterferon/ribavirin in Phase IIb/III studies / O. Lenz, T. Verbinnen, B. Fevery [etal.] // J.
Hepatol. – 2015. – № 62. – P. 1008–1014.134225. Li, M. Interferon-lambdas: the modulators of antivirus,antitumor, and immune responses /M. Li, X. Liu, Y Zhou, S. B. Su // J. Leukoc. Biol. – 2009. – № 86. – P. 23–32.226. Li, K. Activation of chemokine and inflammatory cytokine response in hepatitis C virusinfected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNAintermediates / K. Li [et al.] // Hepatology.
– 2012. – V. 55, № 3. – Р. 666–675.227. Liliane, K. S. ABO/Rh Blood groups and risk of HIV infection and hepatitis B among blooddonors of abidjan, cote d’ivoire / K. S. Liliane, Y. N. Zizendorf, S. Z. Flore [et al.] // European Journalof Microbiology and Immunology. – 2015. – № 5ю – P. 205–209.228. Lindsay, K. L. Hepatitis Interventional Therapy Group. A randomized, double-blind trialcomparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis С/ K.
L. Lindsay, C. Trepo, Т. Heintges [et al.] // Hepatology. – 2001. – № 34 (2). – P. 395–403.229. Lopusna, K. Interferons lambda, new cytokines with antiviral activity / K. Lopusna,I. Rezuchova, T. Betakova [et al.] // Acta Virologica. – 2013. – № 57 (2). – P. 171–179.230. Lozano, R. Global and regional mortality from 235 causes of death for 20 age groups in1990 and 2010: asystematic analysis for the Global Burden of Disease Study 2010 / R.
Lozano,M. Naghavi, K. Foreman [et al.] // Lancet. – 2012 Dec 15. – № 380 (9859). – P. 2095–2128.231. Mallet, V. Brief Communication: the relationship of regression of cirrhosis to outcome inchronic hepatitis C / V. Mallet, H. Gilgenkrantz, J. Serpaggi // Ann. Intern. Med. – 2008. – V. 149,№ 6. – Р. 399–403.232. Mangia A. Individualizing treatment duration in hepatitis C virus genotype 2/3-infectedpatients / A.
Mangia // Liver International. – 2011. – V. 31, № 1. – P. 36–41.233. Manns, M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatmentnaive patients.with chronic hepatitis С virus genot pe 1 infection (QUEST-2): randomised, doubleblind, placebo-controlled phase 3 trial / M. Manns, P. Marcellin, F. Poordad [et al.] // Lancet.
– 2014. –№ 384. – P. 414–426.234. Manns, M. P. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plusribavirin for initial treatment of chronic hepatitis C: a randomised trial / M. P. Manns, J. G.McHutchison, S. C Gordon [et al.] // Lancet. – 2001. – № 358(9286). – P. 958–965.235. Marabita, F. Genetic variation in the interleukin-28B gene is not associated with fibrosisprogression in patients with chronic hepatitis C and known date of infection /F.
Marabita,A. Aghemo, S. De Nicola [et al.] // Hepatology. – 2011. – No. 54. – P. 1127–1134 [doi: 10.1002/hep.24503. pmid:21721028].236. Marcello, Т. Interferons alpha and lambda inhibit hepatitis С virus replication with distinctsignal transduction and gene regulation kinetics / Т. Marcello, A. Grakoui, G. Barba-Spaeth //Gastroenterology. – 2006. – Vol. 131, № 6. – P.
1887–1898.135237. Matsumura, T. 25-Hydroxyvitamin D3 suppresses hepatitis C virus production /T. Matsumura, T. Kato, N. Sugiyama [et al.] // Hepatology. – 2012. – № 56. – P. 1231–1239.238. Mauss, S. Hepatology. A Clinical Textbook / S. Mauss, T. Berg, J. Rockstroh [et al.]. –Third edition. – Flying Publisher, 2012.239. McCarthy, J. J.
Replicated association between anIL28B gene variant and a sustainedresponse to pegylated interferon and ribavirin / J. J. McCarthy, J. H. Li, A Thompson [et al.] //Gastroenterology. – 2010. – № 138. – P. 2307–2314.240. McHutchison, J. G. IDEAL Study Team.
Peginterferon alfa-2b or alfa-2a with ribavirin fortreatment of hepatitis С infection / J. G. McHutchison, E. J. Lawitz, M. L. Shiffman [et al.] // N. Engl.J. Med. – 2009. – № 361ю – P. 580–593.241. Messina, J. P. Global distribution and prevalence of hepatitis С virus genotypes / J. P.Messina, I. Humphreys, A. Flax-man [et al.] // Hepatology. – 2015. – № 61 (1). – P. 77–87.242. Missiha, S.
Impact of Asian race on response to combination therapy with pegylatedinterferon alfa-2a and ribavirin in chronic hepatitis С / S. Missiha, J. Heathcote, T. Arenovich [et al.] //Am. J. Gastroenterol. – 2007. – № 102. – P. 2181–2188.243. Miyashita, Т. Distribution of blood groups in Korea / Т. Miyashita, H.
Hasekura //Hum.Hered. – 1989. –V. 39. – P. 223–229.244. Moon, С. Lower Incidence of Hepatocellular Carcinoma and Cirrhosisin Hepatitis CPatients with Sustained Virological Responseby Pegylated Interferon and Ribavirin / С. Moon,K. Jung, Y. Kim Do [et al.] // Dig. Dis. Sci. – 2014 [doi10.1007/s10620-014-3361-6].245. Mourant, A. E. The Distribution of the Human Blood Groups and Other Polymorphisms /A. E. Mourant, A. C. Kopec, K. Domaniewska-Sobczak. – 2-nd ed.
– London : Oxford UniversityPress, 1976.246. Muir, A. J. Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirinfor the treatment of chronic hepatitis С in blacks and non-Hispanic whites / A. J. Muir, J. D. Bornstein,P. G. Killenberg // N. Engl. J. Med. – 2004. – № 350. – P. 2265–2271.247. Nakamoto, S.
Association between mutations in the cor region of hepatitis C virus genotype1 and hepatocellular carcinoma development / S. Nakamoto, F. Imazeki, K. Fukaiet [et al.] //J. Hepatol. – 2010. – № 52. – P. 72–78.248. Noureddin, M. E. Association of IL28B genotype with fibrosis progression and clinicaloutcomes in patients with chronic hepatitis C: a longitudinal analysis // Hepatology.
– 2013. – № 58. –P. 1548–1557 [doi: 10.1002/hep.26506. pmid:23703931.249. Onsten, T. G. The higher frequency of blood group B in a Brazilian population with HIVinfection / T. G. Onsten, S. M. Callegari-Jacques, L. Z. Goldani // Open AIDS J. – 2013. – № 7. –P. 47–50.136250. Osinusi, A. Retreatment of chronic hepatitis C virus genotype 1 infection after relapse: anopen-label pilot study / A. Osinusi, A. Kohli, M. M. Marti [ et al.] // Ann.
Intern. Med. – 2014. –№ 161. – P. 634–638.251. Patterson, J. L. Molecular mechanisms of action of ribavirin / J. L. Patterson, R. FcmandezLarsson // Rev. Infect. Dis. – 1990. – № 12. – P. 1132–1146.252. Pawlotsky, J. M. NS5A inhibitors in the treatment of hepatitis С / J. M. Pawlotsky // J.Hepatol. – 2013.
– № 59 (2). – P. 375–382.253. Petta, S. Low vitamin D serum level is related to severe fibrosis and low responsiveness tointerferon-based therapy in genotype 1 chronic hepatitis C / S. Petta, C. Cammà, C. Scazzone [et al.] //Hepatology. – 2010. – № 51. – P. 1158–1167.254. Poordad, F. IL28B polymorphism predicts virological response in patients with chronichepatitis С genotype 1 treated with boceprevir (BOC) combination therapy / F.
Poordad, J. P.Bronowicki, S. C. Gordon [et al.] // J. Hepatol. – 2011. – № 54 (suppl 1). – S.6.255. Poordad, F. F. Review article: the role of rapid virological response in determiningtreatment duration for chronic hepatitis C / F. F. Poordad // Aliment.
Pharmacol. Ther. – 2010. –Vol. 31. – Р. 1251–1267.256. Poordad, F. F. Boceprevir for untreated chronic HCV genotype 1 infection / F. F. Poordad,J. Jr. McCone, B. R. Bacon [et al.] // N. Engl. J. Med. – 2011. – № 364. – P. 1195–1206.257. Poynard, T. Impact of interferon Alpha -2b and ribavirin on the liver fibrosis progression inpatients with chronic hepatitis C / T. Poynard, J. Huthcicon, G. L. Davis [et al.] // Hepatology. – 2000.– № 32.
– P. 1131–1137.258. Poynard, T. Impact of Pegylated interferon Alpha -2a and ribavirin on liver fibrosisprogression in patients with chronic hepatitis C / T. Poynard, J. Huthcicon, M. Manns [et al.] //Gastroenterol. – 2002. – № 122. – P. 1303–1313.259. Poynard, T. Randomised trial of interferon al-pha2b plus ribavirin for 48 weeks or for 24weeks versus interferon al-pha2b plus placebo for 48 weeks for treatment of chronic infection withhepatitis C virus / T. Poynard, P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
